| human | Q5 |
| P27 | country of citizenship | Japan | Q17 |
| P108 | employer | National Cancer Center Hospital East | Q55454195 |
| P106 | occupation | researcher | Q1650915 |
| Q53081405 | 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. |
| Q35022783 | A Case of Descending Necrotizing MediastinitisPenetrating to the Esophagus |
| Q37578324 | A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors |
| Q44327458 | A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). |
| Q47597026 | A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer |
| Q33596564 | A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection |
| Q78029389 | A model chemosensitivity test examining apoptosis in small specimens of gastric cancer |
| Q53097011 | A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). |
| Q77847731 | A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms |
| Q88055520 | A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity |
| Q38393041 | A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors |
| Q37028989 | A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer |
| Q86494622 | A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer |
| Q33431483 | A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors |
| Q83900980 | A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Tria |
| Q33341964 | A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410). |
| Q46564784 | A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial |
| Q83447218 | A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus |
| Q37038184 | A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. |
| Q35368335 | A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer |
| Q46842746 | A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer |
| Q49302498 | A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites |
| Q39755186 | Additional surgery for non-curative resection after endoscopic submucosal dissection for gastric cancer: a retrospective analysis of 200 cases |
| Q43273259 | Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients |
| Q42625923 | Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients |
| Q43955817 | Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report |
| Q38971256 | Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer |
| Q33394763 | Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases |
| Q38924049 | Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials |
| Q36530731 | Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies |
| Q28542007 | Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect |
| Q33885980 | Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research |
| Q44177086 | Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer |
| Q34026252 | Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients |
| Q44151716 | Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer |
| Q90587058 | Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials |
| Q90068692 | Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD |
| Q84078596 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial |
| Q29620647 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study |
| Q38413485 | Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing |
| Q44722187 | Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin |
| Q91299957 | Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer |
| Q43860636 | Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. |
| Q74531162 | Carcinoma coexisting with esophageal leiomyoma |
| Q83144606 | Causal relationships between esophageal squamous cell carcinoma and nephrotic syndrome |
| Q112801454 | Characterization of the large‐scale Japanese patient‐derived xenograft (J‐PDX) library |
| Q35992591 | Chemoradiotherapy for esophageal cancer: current status and perspectives |
| Q37155553 | Chemotherapy for metastatic gastric cancer: past, present, and future |
| Q36076767 | Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. |
| Q89974878 | Chronological change in chemo-biologic therapy, gastrointestinal cancer |
| Q44351463 | Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer |
| Q37643988 | Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma |
| Q46102946 | Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan |
| Q53577839 | Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. |
| Q47109685 | Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehen |
| Q100455164 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies |
| Q61805291 | Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer |
| Q54977341 | Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. |
| Q89975256 | Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC |
| Q40581214 | Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients |
| Q50727268 | Clinicopathological, endoscopic, and molecular characteristics of the "skirt" - a new entity of lesions at the margin of laterally spreading tumors. |
| Q34871466 | Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese |
| Q64064250 | Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy |
| Q38882202 | Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). |
| Q53645618 | Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. |
| Q37565108 | Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma |
| Q53631316 | Computer-assisted analysis of biopsy specimen microvessels predicts the outcome of esophageal cancers treated with chemoradiotherapy. |
| Q36244592 | Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma |
| Q35811012 | Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method |
| Q79099814 | Controversies in the treatment of esophageal cancer from the viewpoint of medical oncology |
| Q43518078 | Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer |
| Q53256823 | Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. |
| Q36112140 | Current status and future prospects of chemotherapy for metastatic gastric cancer: a review |
| Q34012967 | Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study |
| Q30785622 | Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. |
| Q36472210 | Disparities in gastric cancer chemotherapy between the East and West |
| Q37141671 | Diverse eastern and Western approaches to the management of gastric cancer. |
| Q44178319 | Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study |
| Q43262124 | Does daily alcohol and/or cigarette consumption cause low-grade dysplasia, a precursor of esophageal squamous cell carcinoma? |
| Q46567504 | Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). |
| Q43206971 | EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma |
| Q73600851 | EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer |
| Q84421532 | Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution |
| Q47237727 | Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. |
| Q37146675 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors |
| Q98575125 | Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis |
| Q90075055 | Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial |
| Q36767776 | Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study |
| Q58694204 | Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma |
| Q44328704 | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey |
| Q46540756 | Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). |
| Q39393733 | Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer |
| Q84531236 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia |
| Q47358505 | Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection |
| Q36078921 | Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study |
| Q45201267 | Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan |
| Q51676975 | Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. |
| Q84033838 | Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer |
| Q53565118 | Endoscopic submucosal dissection using a new scissors-type electrosurgical knife: a first-in-human feasibility study. |
| Q35674222 | Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models. |
| Q53226764 | Epidermoid metaplasia of the esophagus: endoscopic feature and differential diagnosis. |
| Q43725087 | Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma |
| Q46984592 | Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. |
| Q78853372 | Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions |
| Q92814580 | Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts |
| Q33399121 | Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial |
| Q55322223 | Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. |
| Q53158332 | Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. |
| Q54400420 | Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. |
| Q44679439 | Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil |
| Q54218339 | Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. |
| Q83311812 | Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications |
| Q84705705 | Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers |
| Q43414868 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer |
| Q78029438 | Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy |
| Q43264239 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study |
| Q79551981 | Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS) |
| Q44429351 | Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients |
| Q28191037 | Functional Characterization of Wild-type and Variant (T202I and M59I) Human UDP-glucuronosyltransferase 1A10 |
| Q46577270 | Functional analysis of four naturally occurring variants of human constitutive androstane receptor |
| Q46463070 | Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population |
| Q40395346 | Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). |
| Q42876512 | Gastric Cancer Working Group Report |
| Q54477942 | Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib. |
| Q42365301 | Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation |
| Q39295199 | Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant. |
| Q85171688 | Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis |
| Q81527569 | Genetic polymorphisms of UGT1A6 in a Japanese population |
| Q82383679 | Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients |
| Q83349894 | Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population |
| Q80408458 | Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15 |
| Q81166532 | Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences |
| Q46619620 | Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population |
| Q81691372 | Genetic variations and haplotypes of UGT1A4 in a Japanese population |
| Q80895328 | Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population |
| Q38465629 | Globalization of clinical trials |
| Q38347530 | Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan |
| Q47296992 | Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. |
| Q90355846 | Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing |
| Q30652586 | Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data. |
| Q46907839 | Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients |
| Q50581166 | Impaired mental health among the bereaved spouses of cancer patients. |
| Q44027420 | Implantation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamous cell carcinomas. |
| Q48451787 | Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies |
| Q35799385 | Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial) |
| Q47412558 | Integrated safety summary for trifluridine/tipiracil (TAS-102). |
| Q80452767 | Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 |
| Q90247055 | JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer |
| Q46548601 | Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach |
| Q45300740 | Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer |
| Q91685811 | KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer |
| Q27853010 | Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study |
| Q110566364 | Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN |
| Q48012424 | Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma |
| Q36625694 | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
| Q81436311 | Local recurrence of squamous-cell carcinoma of the esophagus after EMR |
| Q90237892 | Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer |
| Q48252275 | Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer. |
| Q80676121 | Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy |
| Q34620968 | Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials |
| Q45197528 | Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study |
| Q44513217 | Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus |
| Q83065708 | Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study |
| Q37709811 | Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer |
| Q37692114 | NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. |
| Q49351167 | Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial |
| Q44458774 | Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study |
| Q40289794 | Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial |
| Q53209050 | Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? |
| Q46812542 | Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. |
| Q44574465 | Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus |
| Q57273153 | Novel Genetic Polymorphisms in the NR3C1 (Glucocorticoid receptor) Gene in a Japanese Population |
| Q82204627 | Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States |
| Q37615896 | Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients |
| Q39769463 | Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial |
| Q89029141 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial |
| Q41595469 | Peritonitis related to percutaneous endoscopic gastrostomy using the direct method for cancer patients. |
| Q91456012 | Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study |
| Q58614911 | Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma |
| Q54547540 | Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. |
| Q92648000 | Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer |
| Q54393532 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. |
| Q37121517 | Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer |
| Q35889628 | Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors |
| Q33710548 | Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer |
| Q33402421 | Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors |
| Q52773451 | Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). |
| Q36503472 | Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors |
| Q54599564 | Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. |
| Q42859969 | Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors |
| Q33566872 | Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors |
| Q35051964 | Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors |
| Q34085148 | Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors |
| Q92455704 | Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies |
| Q36621566 | Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer |
| Q35051852 | Phase I study of olaratumab in Japanese patients with advanced solid tumors |
| Q83347957 | Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors |
| Q33400146 | Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. |
| Q82751720 | Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck |
| Q33371147 | Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer |
| Q84869381 | Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI |
| Q43281012 | Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate |
| Q33424985 | Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604) |
| Q51538482 | Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906) |
| Q53149355 | Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck. |
| Q33348280 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer |
| Q44908377 | Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma |
| Q33376015 | Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines |
| Q45034321 | Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 960 |
| Q34056960 | Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. |
| Q30787014 | Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer |
| Q93086621 | Poster abstracts of the 18th Pan Arab Cancer Congress. TUNISIA. April 19-21, 2018 |
| Q37706868 | Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. |
| Q90975662 | Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer |
| Q44629355 | Present status of chemotherapy for colorectal cancer in countries outside of Japan |
| Q33849290 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data |
| Q39038837 | Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients |
| Q39834652 | Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery |
| Q43870660 | Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy |
| Q37197679 | Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis |
| Q51750620 | Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. |
| Q37528049 | Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma. |
| Q89553736 | Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial |
| Q39625948 | Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan |
| Q33398232 | Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma |
| Q55319545 | QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. |
| Q33829785 | Quality of life in the trastuzumab for gastric cancer trial |
| Q38272318 | Ramucirumab for gastric cancer |
| Q29620917 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial |
| Q46350650 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). |
| Q64109947 | Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing r |
| Q40613157 | Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). |
| Q33417630 | Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations |
| Q41741632 | Randomized trial of TAS-102 for refractory metastatic colorectal cancer |
| Q91673708 | Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer |
| Q48569564 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. |
| Q91259894 | Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials |
| Q38951620 | Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. |
| Q80730902 | Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP |
| Q91422883 | Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma |
| Q26766039 | Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs |
| Q42730356 | Retrospective analysis of antiemetic effect in patients receiving cisplatin |
| Q45271628 | Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region |
| Q110566220 | SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors |
| Q34023788 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies |
| Q53837214 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. |
| Q87001982 | Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution |
| Q33423976 | Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma |
| Q84461270 | Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors |
| Q55073748 | Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. |
| Q37157346 | Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer |
| Q52900371 | Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. |
| Q78029373 | Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis |
| Q53005714 | Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. |
| Q78029461 | Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer |
| Q80375553 | Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin |
| Q34978610 | Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. |
| Q48846698 | Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites |
| Q38401300 | Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer |
| Q41443108 | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. |
| Q84974747 | Successful endosocpic submucosal dissection for esophageal squamous cell carcinoma together with a lipoma |
| Q44012763 | Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. |
| Q34604499 | Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. |
| Q43472706 | TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial |
| Q47308849 | TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study |
| Q54394567 | TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy. |
| Q112347109 | The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer |
| Q28681140 | The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 [...] |
| Q46907708 | The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status |
| Q110566356 | The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer |
| Q110566359 | The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer |
| Q110566355 | The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer |
| Q110566360 | The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced esophageal cancer |
| Q110566354 | The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Scree |
| Q35211663 | The latest advances in chemotherapy for gastrointestinal cancers |
| Q110566365 | The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC) |
| Q35139161 | The role of chemotherapy in the current treatment of gastric cancer |
| Q47560805 | The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer |
| Q43056334 | Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab |
| Q45201194 | Three novel single nucleotide polymorphisms in UGT1A10. |
| Q81197213 | Three novel single nucleotide polymorphisms in UGT1A9 |
| Q33440401 | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study |
| Q27851578 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial |
| Q44012031 | Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer |
| Q104067114 | Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer |
| Q28299967 | Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2) |
| Q50098778 | Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population |
| Q44922991 | UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer |
| Q50950240 | Usefulness of endoscopic radial incision and cutting method for refractory esophagogastric anastomotic stricture (with video). |
| Q110569502 | Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis |
| Q110569489 | Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined an |
| Q110569495 | Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis |
| Q39203869 | Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial |
| Q85595137 | [109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium:1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents antibody therapy; introduction] |
| Q83796934 | [Chemoradiotherapy] |
| Q86437184 | [Chemotherapy with molecular targeting agents for colorectal cancer] |
| Q45951763 | [Current Status and Future Perspectives of SCRUM-Japan]. |
| Q95621515 | [Current status and issues in early & exploratory oncology clinical trials in Japan] |
| Q64967627 | [Current topics on molecular targeting drugs for gastric cancer]. |
| Q80083618 | [Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer] |
| Q57212452 | [Participation to international registration trials--from the investigator's standpoint] |
| Q45960431 | [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. |
| Q37928535 | mTOR as a therapeutic target in patients with gastric cancer |
Search more.